150 related articles for article (PubMed ID: 38188613)
41. Prognostic Value of Cancer Stem Cell Markers CD44 and ALDH1/2 in Gastric Cancer Cases.
Senel F; Kökenek Unal TD; Karaman H; Inanç M; Aytekin A
Asian Pac J Cancer Prev; 2017 Sep; 18(9):2527-2531. PubMed ID: 28952294
[TBL] [Abstract][Full Text] [Related]
42. Expression of PD-L1, cancer stem cell and epithelial-mesenchymal transition phenotype in non-small cell lung cancer.
Koh YW; Han JH; Haam S
Pathology; 2021 Feb; 53(2):239-246. PubMed ID: 33036771
[TBL] [Abstract][Full Text] [Related]
43. BR-BCSC Signature: The Cancer Stem Cell Profile Enriched in Brain Metastases that Predicts a Worse Prognosis in Lymph Node-Positive Breast Cancer.
Dionísio MR; Vieira AF; Carvalho R; Conde I; Oliveira M; Gomes M; Pinto MT; Pereira P; Pimentel J; Souza C; Marques MMC; Duval da Silva V; Barroso A; Preto D; Cameselle-Teijeiro JF; Schmitt F; Ribeiro AS; Paredes J
Cells; 2020 Nov; 9(11):. PubMed ID: 33182375
[TBL] [Abstract][Full Text] [Related]
44. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
[TBL] [Abstract][Full Text] [Related]
45. [Expression Level of Membrane-associated Proteins Numb in Epithelial Ovarian Carcinoma and Its Relationship with Ovarian Cancer Stem Cell Markers CD117, CD133, ALDH1.].
Jing H; Liu XY; Chen YL; Bai LP; Zheng A
Sichuan Da Xue Xue Bao Yi Xue Ban; 2016 Nov; 47(6):878-882. PubMed ID: 28598117
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of expression of cancer stem cell markers and fusion gene in synovial sarcoma: Insights into histogenesis and pathogenesis.
Zhou Y; Chen D; Qi Y; Liu R; Li S; Zou H; Lan J; Ju X; Jiang J; Liang W; Shen Y; Pang L; Li F
Oncol Rep; 2017 Jun; 37(6):3351-3360. PubMed ID: 28498445
[TBL] [Abstract][Full Text] [Related]
47. ALDH1 expression correlates with an epithelial-like phenotype and favorable prognosis in lung adenocarcinoma: a study based on immunohistochemistry and mRNA expression data.
Koh YW; Han JH; Haam S; Jung J
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1427-1436. PubMed ID: 30923946
[TBL] [Abstract][Full Text] [Related]
48. ALDH(+)/CD44(+) cells in breast cancer are associated with worse prognosis and poor clinical outcome.
Qiu Y; Pu T; Guo P; Wei B; Zhang Z; Zhang H; Zhong X; Zheng H; Chen L; Bu H; Ye F
Exp Mol Pathol; 2016 Feb; 100(1):145-50. PubMed ID: 26687806
[TBL] [Abstract][Full Text] [Related]
49. Lack of CD44 and Sox-2 Overexpression as Two Independent Favourable Prognostic Factors in HPV Positive Patients with Oropharyngeal Cancers.
Kołodziej-Rzepa M; Biesaga B; Janecka-Widła A; Mucha-Małecka A
Pathobiology; 2022; 89(4):205-213. PubMed ID: 35078199
[TBL] [Abstract][Full Text] [Related]
50. Additional Prognostic Value of Lymph Node Ratio (LNR) and Number of Negative Lymph Nodes (NLNs) in Chinese Patients with Triple Negative Breast Cancer.
Wang QX; Cai YF; Chen YY; Zhang W; Jin WX; Chen ED; Zhang XH; Li Q
Ann Clin Lab Sci; 2017 Jan; 47(1):68-75. PubMed ID: 28249920
[TBL] [Abstract][Full Text] [Related]
51. The role of ALDH1A1 in contributing to breast tumour aggressiveness: A study conducted in an African population.
Gyan E; Green A; Ahenkorah-Fondjo L; Jackson A; Toss MS; Akakpo PK; Derkyi-Kwarteng L; Rahman GA; Owiredu W
Ann Diagn Pathol; 2021 Apr; 51():151696. PubMed ID: 33460998
[TBL] [Abstract][Full Text] [Related]
52. Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency.
Atkinson RL; Yang WT; Rosen DG; Landis MD; Wong H; Lewis MT; Creighton CJ; Sexton KR; Hilsenbeck SG; Sahin AA; Brewster AM; Woodward WA; Chang JC
Breast Cancer Res; 2013; 15(5):R77. PubMed ID: 24008095
[TBL] [Abstract][Full Text] [Related]
53. Cancer stem cell markers ALDH1 and CD44+/CD24- phenotype and their prognosis impact in invasive ductal carcinoma.
Rabinovich I; Sebastião APM; Lima RS; Urban CA; Junior ES; Anselmi KF; Elifio-Esposito S; De Noronha L; Moreno-Amaral AN
Eur J Histochem; 2018 Sep; 62(3):. PubMed ID: 30362671
[TBL] [Abstract][Full Text] [Related]
54. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
[TBL] [Abstract][Full Text] [Related]
55. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers.
Olsson E; Honeth G; Bendahl PO; Saal LH; Gruvberger-Saal S; Ringnér M; Vallon-Christersson J; Jönsson G; Holm K; Lövgren K; Fernö M; Grabau D; Borg A; Hegardt C
BMC Cancer; 2011 Sep; 11():418. PubMed ID: 21957977
[TBL] [Abstract][Full Text] [Related]
56. Stem cell marker aldehyde dehydrogenase 1 (ALDH1)-expressing cells are enriched in triple-negative breast cancer.
Li H; Ma F; Wang H; Lin C; Fan Y; Zhang X; Qian H; Xu B
Int J Biol Markers; 2013 Dec; 28(4):e357-64. PubMed ID: 24338721
[TBL] [Abstract][Full Text] [Related]
57. Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer.
Seo AN; Lee HJ; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY
Br J Cancer; 2016 May; 114(10):1109-16. PubMed ID: 27115469
[TBL] [Abstract][Full Text] [Related]
58. Cancer Stem Cell Markers, CD44 and ALDH1, for Assessment of Cancer Risk in OPMDs and Lymph Node Metastasis in Oral Squamous Cell Carcinoma.
Dhumal SN; Choudhari SK; Patankar S; Ghule SS; Jadhav YB; Masne S
Head Neck Pathol; 2022 Jun; 16(2):453-465. PubMed ID: 34655409
[TBL] [Abstract][Full Text] [Related]
59. Breast cancer stem cells expressing different stem cell markers exhibit distinct biological characteristics.
Shao J; Fan W; Ma B; Wu Y
Mol Med Rep; 2016 Dec; 14(6):4991-4998. PubMed ID: 27840965
[TBL] [Abstract][Full Text] [Related]
60. Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer.
Riaz N; Idress R; Habib S; Lalani EN
Front Oncol; 2020; 10():1083. PubMed ID: 32850312
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
